Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.

Previously healthy children hospitalized with respiratory syn- cytial virus (RSV) received motavizumab (3, 15, or 30 mg/kg intrave- nously), an RSV-specific monoclonal antibody, or placebo. Safety, toler- ability, motavizumab concentrations, and immunogenicity were assessed. Cultivatable RSV in the upper respiratory tract was significantly reduced with motavizumab compared with placebo day 1 post-treatment. No adverse events were considered motavizumab-related by site investigators.